Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Meningioma-Brain Crosstalk: A Scoping Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Pathologic Characteristics of Pregnancy-Related Meningiomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Long-Term Follow-Up and Predictors of Functional Outcome after Surgery for Spinal Meningiomas: A Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. TAM Receptor Inhibition-Implications for Cancer and the Immune System

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

The incidence of cancer is increasing worldwide, which is to a large extent related to the population's increasing lifespan. However, lifestyle changes in the Western world are causative as well. Exercise is intrinsically associated with what one could call a "healthy life", and physical activity is associated with a lower risk of various types of cancer. Mouse models of exercise have shown therapeutic efficacy across numerous cancer models, at least in part due to the secretion of adrenaline, which mobilizes cells of the immune system, i.e., cytotoxic T and natural killer (NK) cells, through signaling of the β-2 adrenergic receptor (β2AR). Clinical trials aiming to investigate the clinical value of exercise are ongoing. Strikingly, however, the use of β-blockers-antagonists of the very same signaling pathway-also shows signs of clinical potential in cancer therapy. Cancer cells also express β-adrenergic receptors (βARs) and signaling of the receptor is oncogenic. Moreover, there are data to suggest that β2AR signaling in T cells renders the cell functionally suppressed. In this paper, we discuss these seemingly opposing mechanisms of cancer therapy-exercise, which leads to increased β2AR signaling, and β-blocker treatment, which antagonizes that same signaling-and suggest potential mechanisms and possibilities for their combination.

OriginalsprogEngelsk
Artikelnummer394
TidsskriftCancers
Vol/bind13
Udgave nummer3
Sider (fra-til)1-16
Antal sider16
ISSN2072-6694
DOI
StatusUdgivet - feb. 2021

ID: 65949999